Last participant has been randomized and dosed in the Phase 3 APOLLO study of bitopertin in erythropoietic protoporphyria (EPP) The study size was expanded to 183 participants due to patient and ...
The MarketWatch News Department was not involved in the creation of this content. -- Patients receiving camoteskimab had a clinically meaningful and statistically significant reduction in mean EASI ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results